Pharma & Biotech Global Week in Review 27 July 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Corporate self-interest and strategic choices: Gilead licenses to Medicines Patent Pool (IP Watch) (KEI)

Glybera (Alipogene tiparvovec) – EU: EMA continues to defer approval of first gene therapy application in Europe (Patent Docs)

Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of equivalents: Duramed Pharmaceuticals, Inc. v. Paddock Laboratories, Inc. (IPBiz) (Patently-O) (Patent Docs) (GenericsWeb)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Decision for WIPO GA 49: Matters concerning the IGC on IP and genetic resources, traditional knowledge and folklore (KEI) (IP Watch) (IP Watch)

Corporate self-interest and strategic choices: Gilead licenses to Medicines Patent Pool (IP Watch) (KEI)

Global biotechnology IP evaluation by Scientific American (BIOtechNOW)

The Bucknell book – ‘Pharmaceutical, Biotechnology and Chemical Inventions: World Protection and Exploitation’ (The SPC Blog)

Dr Reddy’s finds complex generics a good bet (GenericsWeb)

EU: SPCs and combination products – AG opinion in C-322/10 Medeva and C-422/10 Georgetown University (Kluwer Patent Blog) (The SPC Blog)

India: Patent discrimination against indigenous communities? – ICMR documenting Andamans indigenous communities’ TK, helping them to patent it (Spicy IP)

Kenya opens region’s door to GM maize (IP Watch)

US: Who cares about patent term?: Biotechnology patent applicants (Patently-O)

US: Bayh Dole Act a failure? (BIOtechNOW) (BIOtechNOW)

US: Bill prohibiting reverse payments voted out of Committee (Patent Docs)

US: The scope of new chemical entity exclusivity and FDA’s “umbrella” exclusivity policy (FDA Law Blog)

US: FDA issues draft guidance, “510(k) Device Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device” (FDA Law Blog)

US: Will the fourth time be the charm? FDA is once again asked for guidance on drug delivery device patent Orange Book listing (this time by Forest Laboratories) (FDA Law Blog)

US: Bio/Pharma legislation watch – Stem Cell Research Advancement Act of 2011, Confirming Genetic Diagnostic Test Activity Legislation, Medical Innovation Prize Fund Act, Seed Availability and Competition Act of 2011, Patent Continuing Disclosure Act (Patent Docs)

US: District Court says “shall” means “must” in challenge to PTO denial of interim patent term extension: Genetics & IVF Institute v Kappos (FDA Law Blog)

US: Myriad Genetics files amicus briefs in joint infringement cases Akamai and McKesson (Holman’s Biotech IP Blog)

US: TTAB 2(d) reversal: ‘EPs 7630’ not confusingly similar to ‘EP’ for respiratory drugs: In re Dr. Willmar Schwabe GmbH & Co. KG (TTABlog)

US: ALJ Rogers sets 17-month target date in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)

 

Products

Alimta (Pemetrexed) – US: Eli Lilly files patent infringement complaints against APP Pharmaceuticals in Delaware and S D Indiana in response to Para IV certification filing (Patent Docs)

Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of equivalents: Duramed Pharmaceuticals, Inc. v. Paddock Laboratories, Inc. (IPBiz) (Patently-O) (Patent Docs) (GenericsWeb)

Copaxone (Glatiramer) – US: Mylan and Momenta challenge Teva patent on Copaxone (IPBiz)

Gemzar (Gemcitabine) – US: Strides Arcolab announces US FDA approval for Gemcitabine for injections USP (GenericsWeb)

Glybera (Alipogene tiparvovec) – EU: EMA continues to defer approval of first gene therapy application in Europe (Patent Docs)

Jalyn (Dutasteride, Tamsulosin) – US: Watson files ANDA to market generic Jalyn, Glaxo responds within 30 days with lawsuit (GenericsWeb)

Loprox (Cicloprox) – US: Medicis files patent infringement suits against Nycomed, Perrigo and Taro based on Nycomed’s generic version of Loprox (Patent Docs)

Lotrel (Amlodipine, Benazepril) – US: Teva settles litigation with Novartis over generic Lotrel (GenericsWeb)

MetroGel (Metronidazole) – US: Galderma files patent infringement suit against Tolmar over ANDA to manufacture generic MetroGel (Patent Docs)

Nexium (Esomeprazole) – Denmark: Process patent, Bailiff’s Court Frederiksberg upholds injunction against API manufacturer (Kluwer Patent Blog)

Nexium (Esomeprazole) – UK: EWHC (Pat) grants Ranbaxy’s request for declaration of non-infringement in respect of AstraZeneca patent where main claim at issue is in ‘Swiss form’ (EPLAW)

Oxycodone – Norway: Borgarting Appelate Court finds novelty and inventive step requirements satisfied, infringement of one patents in suit: Mundipharma v Ratiopharma (Kluwer Patent Blog)

Ponstel (Mefenamic) – US: Prasco announces authorised generic agreement with Shionogi (GenericsWeb)

Prezista (Darunavir) – US: Tibotec files patent infringement complaint against Lupin in response to Para IV certification filing (Patent Docs)

Valsartan – Norway: Oslo District Court: Infringement assessment to be made at time of alleged infringement, not priority date; SPC protects both mono and combination products with Valsartan and Hydrochlorotiazide (Kluwer Patent Blog)

Vyvanse (Lisdexamfetamine) – US: Shire files patent infringement complaints against Actavis and Mylan in response to Para IV certification filings (Patent Docs)

One Comment on “Pharma & Biotech Global Week in Review 27 July 2011 from IP Think Tank

  1. Pingback: Patent Baristas » Blawg Review #313

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 20,525 other followers

%d bloggers like this: